PT - JOURNAL ARTICLE AU - Fabienne B. Fischer AU - Melina Bigler AU - Daniel Mäusezahl AU - Jan Hattendorf AU - Adrian Egli AU - Timothy R. Julian AU - Franziska Rölli AU - Valeria Gaia AU - Monica Wymann AU - Françoise Fridez AU - Stefanie Bertschi AU - the SwissLEGIO Hospital Network TI - Legionnaires’ disease in Switzerland: Rationale and study protocol of a prospective national case-control and molecular source attribution study (<em>SwissLEGIO</em>) AID - 10.1101/2022.10.21.21265377 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.21.21265377 4099 - http://medrxiv.org/content/early/2022/10/22/2022.10.21.21265377.short 4100 - http://medrxiv.org/content/early/2022/10/22/2022.10.21.21265377.full AB - Switzerland has one of the highest annual Legionnaires’ disease (LD) notification rates in Europe (7.8 cases/ 100,000 population in 2021). The main sources of infection and the cause for this high rate remain largely unknown. This hampers the implementation of targeted Legionella spp. control efforts. The SwissLEGIO national case-control and molecular source attribution study investigates risk factors and infection sources for community-acquired LD in Switzerland. Over the duration of one year, the study is recruiting 205 newly diagnosed LD patients through a network of 20 university and cantonal hospitals. Healthy controls matched for age, sex, and residence at district level are recruited from the general population. Risk factors for LD are assessed in questionnaire-based interviews. Clinical and environmental Legionella spp. isolates are compared using whole genome sequencing (WGS). Direct comparison of sero- and sequence types (ST), core genome multilocus sequencing types (cgMLST), and single nucleotide polymorphisms (SNPs) between clinical and environmental isolates are used to investigate infection sources and the prevalence and virulence of different Legionella spp. strains detected across Switzerland. The SwissLEGIO study innovates in combining case-control and molecular typing approaches for source attribution on a national level outside an outbreak setting. The study provides a unique platform for national Legionellosis and Legionella research and is conducted in an inter- and transdisciplinary, co-production approach involving various national governmental and national research stakeholders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe SwissLEGIO project is funded by the Federal Office of Public Health (FOPH, grant nr.: 142004673). For the molecular source attribution we acknowledge financial support from the Federal Food Safety and Veterinary Office, the FOPH and the Federal Office of Energy through the project LeCo (Legionella Control in Buildings; Aramis nr.: 4.20.01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Commission of Northwestern and Central Switzerland gave ethical approval for this work (nr.: 2022-00880).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable, as the manuscript constitutes a research protocol.